Imlygic (Talimogene Laherparepvec)

Imlygic is an oncolytic viral therapy used in the management of advanced melanoma.

• Unresectable stage III melanoma: provides local tumor control and may stimulate systemic anti‑tumor immunity.
• Unresectable stage IV melanoma: aims to reduce tumor burden and improve disease control.
• Advanced cutaneous melanoma not amenable to surgery: offers a targeted intralesional treatment option.

• Talimogene laherparepvec is a genetically engineered herpes simplex virus type‑1 that selectively infects and replicates within malignant cells. The virus induces oncolysis, releasing tumor antigens, and expresses granulocyte‑macrophage colony‑stimulating factor (GM‑CSF) to enhance local immune activation and promote a systemic anti‑tumor immune response.

Imlygic may cause a range of adverse reactions following intralesional administration.

Common Side Effects

• Injection site pain: discomfort at the injection site.
• Flu‑like symptoms: fever, chills, and fatigue.
• Nausea: mild to moderate upset stomach.
• Headache: transient headache after treatment.
• Redness or swelling: localized inflammation.
• Fatigue: general tiredness.

Serious or Rare Side Effects

• Cellulitis: bacterial infection of the skin.
• Herpetic infection: spread of HSV to adjacent tissue.
• Tumor necrosis: extensive tissue death at injection site.
• Systemic infection: rare systemic viral dissemination.
• Severe allergic reaction: anaphylaxis or hypersensitivity.
• Autoimmune phenomena: rare immune‑mediated events.

Before using Imlygic, clinicians should consider several safety measures.

• Patient selection: ensure the patient has unresectable stage III/IV melanoma and no contraindicating conditions.
• Immunocompromised status: avoid in patients with severe immunosuppression or active infections.
• Prior HSV exposure: assess history of herpes infections; monitor for reactivation.
• Pregnancy and lactation: use only if potential benefit justifies potential risk; data are limited.
• Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imlygic may interact with other therapies that affect immune function.

Major Interactions (Avoid)

• Live vaccines: concurrent administration may increase risk of vaccine‑related infection.
• Systemic immunosuppressants: may diminish oncolytic efficacy and increase viral spread.

Moderate Interactions (Monitor Closely)

• Antiviral agents (e.g., acyclovir): could reduce viral replication and therapeutic effect.
• Cytokine‑targeting drugs: may alter immune response to the virus.
• Other intralesional therapies: assess cumulative local tissue effects.